Revolutionary technology enables cardiologists to make better decisions and results in 30% assumed revenue growth by the end of 2019; Itamar Medical has a $6.8B addressable market with limited competition; we start our coverage with a price target of 1.51 NIS. Post author:jaimeuss_admin Post published:2 בOctober 2018 Post category:Research Continue ReadingRevolutionary technology enables cardiologists to make better decisions and results in 30% assumed revenue growth by the end of 2019; Itamar Medical has a $6.8B addressable market with limited competition; we start our coverage with a price target of 1.51 NIS.
BiolineRx: Continued advancement and execution of BiolineRx’s lead oncology project – BL-8040; sufficient funds to support clinical strategy; stock target price remains at NIS 5.15 Post author:jaimeuss_admin Post published:30 בAugust 2018 Post category:Research Continue ReadingBiolineRx: Continued advancement and execution of BiolineRx’s lead oncology project – BL-8040; sufficient funds to support clinical strategy; stock target price remains at NIS 5.15
BioLineRx Ltd.: Company is on track with its execution of multiple clinical development programs for the Company’s lead project – BL-8040; Sufficient funds to support this development; Stock price target raised to NIS 5.15 Post author:jaimeuss_admin Post published:30 בAugust 2018 Post category:Research Continue ReadingBioLineRx Ltd.: Company is on track with its execution of multiple clinical development programs for the Company’s lead project – BL-8040; Sufficient funds to support this development; Stock price target raised to NIS 5.15
BioLineRx Ltd.: Continued execution of multiple clinical development programs for the Company’s lead project – BL-8040; Investment by a principal investor reflects confidence in the company’s strategy. Target Price unchanged. Post author:jaimeuss_admin Post published:30 בAugust 2018 Post category:Research Continue ReadingBioLineRx Ltd.: Continued execution of multiple clinical development programs for the Company’s lead project – BL-8040; Investment by a principal investor reflects confidence in the company’s strategy. Target Price unchanged.
BiolineRX is on track with its execution of multiple clinical development programs for the Company’s lead product – BL-8040; the company has sufficient cash until H1-2020; target price remains unchanged as company’s clinical development is in line with our expectations Post author:jaimeuss_admin Post published:30 בAugust 2018 Post category:Research Continue ReadingBiolineRX is on track with its execution of multiple clinical development programs for the Company’s lead product – BL-8040; the company has sufficient cash until H1-2020; target price remains unchanged as company’s clinical development is in line with our expectations
BiolineRx. An Opportunity to Invest in the Development of Unique Cancer Treatment Technologies Post author:jaimeuss_admin Post published:30 בAugust 2018 Post category:Research Continue ReadingBiolineRx. An Opportunity to Invest in the Development of Unique Cancer Treatment Technologies
BioLineRx Ltd.: Additional Investment by A Principal Investor Reflects a Confidence in the Company. Target Price Unchanged Post author:jaimeuss_admin Post published:30 בAugust 2018 Post category:Research Continue ReadingBioLineRx Ltd.: Additional Investment by A Principal Investor Reflects a Confidence in the Company. Target Price Unchanged